Lessons Learned from Two Decades of Anticancer Drugs
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Tremendous efforts have been made to elucidate the basis of cancer biology with the aim of promoting anticancer drug development. Especially over the past 20 years, anticancer drug development has developed from conventional cytotoxic agents to target-based and immune-related therapies. Consequently, more than 200 anticancer drugs are available on the market. However, anticancer drug development still suffers high attrition during the later phases of clinical development and is considered to be a difficult and risky therapeutic category within the drug development arena. The disappointing performance of investigational anticancer candidates implies that there are some shortcomings in the translation of preclinical in vitro and in vivo models to humans, and that heterogeneity in the patient population presents a significant challenge. Here, we summarize both successful and failed experiences in anticancer development during the past 20 years and help identify why the current paradigm may be suboptimal. We also offer potential strategies for improvement.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dose translation from animal to human studies revisited.
Reagan‐Shaw, S., Nihal, M., & Ahmad, N. (2008) · The FASEB Journal · doi:10.1096/fj.07-9574lsf · Cited by 6,524
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
The distribution of secondary growths in cancer of the breast.
Paget, S. (1889) · The Lancet · doi:10.1016/s0140-6736(00)49915-0 · Cited by 5,277
A New Initiative on Precision Medicine
Collins, F. S., & Varmus, H. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1500523 · Cited by 5,202
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Rupaimoole, R., & Slack, F. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.246 · Cited by 4,741
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681 · cited 3×
“With the range cancer drug resistance mechanisms, it seems unlikely that the dream of a ‘magic bullet’ to cure cancer will ever be realized [119].”
BackgroundInfluentialCan the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609 · cited 1×
“Often, tumors display multiple drug resistance (MDR), which is one of the major reasons for the ineffectiveness and toxicity of chemotherapeutic agents [122].”
BackgroundHow many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Raise standards for preclinical cancer research
Begley, C. G., & Ellis, L. M. (2012) · Nature · doi:10.1038/483531a · Cited by 2,979
ClinVar: public archive of interpretations of clinically relevant variants
Landrum, M. J., Lee, J. M., Benson, M., Brown, G., Chao, C., Chitipiralla, S., Gu, B., Hart, J., Hoffman, D., Hoover, J., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1222 · Cited by 2,758
Mechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643 · cited 1×
“Acquired resistance occurs during the cancer development process, which can involve subcloning of tumor somatic mutations, increased target expression levels, and recruitment of alternative compensatory signaling pathways [120].”
BackgroundSystematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456 · cited 9×
“Cancer phenotypes can be observed in cell lines and, thus, compounds that disrupt that phenotype may be viable drugs.”
BackgroundMethodInfluentialDrugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
COSMIC: somatic cancer genetics at high-resolution
Forbes, S. A., Beare, D., Boutselakis, H., Bamford, S., Bindal, N., Tate, J., Cole, C. G., Ward, S., Dawson, E., Ponting, L., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1121 · Cited by 1,922
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
Organoids as an in vitro model of human development and disease
Fatehullah, A., Tan, S. H., & Barker, N. (2016) · Nature Cell Biology · doi:10.1038/ncb3312 · Cited by 1,508 · cited 1×
“Furthermore, some novel animal models, such as 3D organoid-based cell line xenografts, may also offer alternative means to further update and improve animal model performance [90].”
BackgroundPatient-derived tumour xenografts as models for oncology drug development
Tentler, J. J., Tan, A. C., Weekes, C. D., Jimeno, A., Leong, S., Pitts, T. M., Arcaroli, J. J., Messersmith, W. A., & Eckhardt, S. G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.61 · Cited by 1,277
Organs-on-chips at the frontiers of drug discovery
Esch, E. W., Bahinski, A., & Huh, D. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4539 · Cited by 1,185
Gene therapy returns to centre stage
Naldini, L. (2015) · Nature · doi:10.1038/nature15818 · Cited by 1,184
Ashley, E. A. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.86 · Cited by 1,116
Metabolic requirements for the maintenance of self-renewing stem cells
Ito, K., & Suda, T. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3772 · Cited by 1,014
Merlos-Suárez, A., Barriga, F. M., Jung, P., Iglesias, M., Céspedes, M. V., Rossell, D., Sevillano, M., Hernando-Momblona, X., da Silva-Diz, V., Muñoz, P., et al. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2011.02.020 · Cited by 934
Intratumor Heterogeneity: Evolution through Space and Time
Swanton, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2217 · Cited by 931
Sequist, L. V., Martins, R. G., Spigel, D., Grunberg, S. M., Spira, A., Jänne, P. A., Joshi, V. A., McCollum, D., Evans, T. L., Muzikansky, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8494 · Cited by 820 · cited 1×
“However, the evolving tumor acquires a new gatekeeper mutation, named EGFR-T790M, to maintain the genetic information and control the tumor growth, which causes 50% of patients to experience drug resistance and, ultimately, treatment failure [128].”
BackgroundNanomedicine therapeutic approaches to overcome cancer drug resistance
Markman, J. L., Rekechenetskiy, A., Holler, E., & Ljubimova, J. Y. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.019 · Cited by 733 · cited 1×
“Novel strategies, such as nanomedicine targeting the CSC microenvironment, are also being explored [172,173].”
BackgroundMYC/PGC-1α Balance Determines the Metabolic Phenotype and Plasticity of Pancreatic Cancer Stem Cells
Sancho, P., Burgos-Ramos, E., Tavera, A., Bou Kheir, T., Jagust, P., Schoenhals, M., Barneda, D., Sellers, K., Campos-Olivas, R., Graña, O., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.08.015 · Cited by 722
Statistical practice in high-throughput screening data analysis
Malo, N., Hanley, J. A., Cerquozzi, S., Pelletier, J., & Nadon, R. (2006) · Nature Biotechnology · doi:10.1038/nbt1186 · Cited by 721
Precision medicine for cancer with next-generation functional diagnostics
Friedman, A. A., Letai, A., Fisher, D. E., & Flaherty, K. T. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4015 · Cited by 570 · cited 1×
“Targeted cancer therapy is a mainstay of precision medicine and is considered an indispensable component of current anticancer drug development [131].”
BackgroundScreening out irrelevant cell-based models of disease
Horvath, P., Aulner, N., Bickle, M., Davies, A. M., Nery, E. D., Ebner, D., Montoya, M. C., Östling, P., Pietiäinen, V., Price, L. S., et al. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.175 · Cited by 525
The discovery of first-in-class drugs: origins and evolution
Eder, J., Sedrani, R., & Wiesmann, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4336 · Cited by 514 · cited 1×
“There is some debate over which technology contributes more to the discovery of first-in-class drugs [33,34].”
BackgroundPhenotypic screening in cancer drug discovery — past, present and future
Moffat, J. G., Rudolph, J., & Bailey, D. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4366 · Cited by 507 · cited 2×
“Between 1999 and 2013, 21 of 31 oncology new molecule entities (NMEs) discovered by target-based approaches were kinase inhibitors [32].”
BackgroundAssessing and reporting heterogeneity in treatment effects in clinical trials: a proposal
Kent, D. M., Rothwell, P. M., Ioannidis, J. P., Altman, D. G., & Hayward, R. A. (2010) · Trials · doi:10.1186/1745-6215-11-85 · Cited by 504
Inconsistency in large pharmacogenomic studies
Haibe-Kains, B., El-Hachem, N., Birkbak, N. J., Jin, A. C., Beck, A. H., Aerts, H. J. W. L., & Quackenbush, J. (2013) · Nature · doi:10.1038/nature12831 · Cited by 499 · cited 2×
“One example is the inconsistency between two large drug-response data sets from the Cancer Cell Line Encyclopedia (CCLE) [30] and the Genomics of Drug Sensitivity in Cancer [31] based on cell-based HTS assays [55].”
BackgroundEstablishment of human tumor xenografts in immunodeficient mice
Morton, C. L., & Houghton, P. J. (2007) · Nature Protocols · doi:10.1038/nprot.2007.25 · Cited by 489
The role of tumour-stromal interactions in modifying drug response: challenges and opportunities
McMillin, D. W., Negri, J. M., & Mitsiades, C. S. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3870 · Cited by 474
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
Chen, Z., Cheng, K., Walton, Z., Wang, Y., Ebi, H., Shimamura, T., Liu, Y., Tupper, T., Ouyang, J., Li, J., et al. (2012) · Nature · doi:10.1038/nature10937 · Cited by 446 · cited 2×
“One promising example of the application of the GEM model for anticancer development is selumetinib (clinical Phase I/II/III), which is designed for the treatment of multiple cancer types, including triple-negative breast cancer [84], nonsquamous cell lung cancer [85], pancreatic cancer [86], and neurofibroma [87,88].”
BackgroundMeric-Bernstam, F., Brusco, L., Shaw, K., Horombe, C., Kopetz, S., Davies, M. A., Routbort, M., Piha-Paul, S. A., Janku, F., Ueno, N., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.4165 · Cited by 424 · cited 1×
“Furthermore, there are concerns over how many patients would benefit from precision medicine [139,140].”
BackgroundPharmacogenomic agreement between two cancer cell line data sets
The Cancer Cell Line Encyclopedia Consortium, & The Genomics of Drug Sensitivity in Cancer Consortium (2015) · Nature · doi:10.1038/nature15736 · Cited by 418
Activation of PKA leads to mesenchymal-to-epithelial transition and loss of tumor-initiating ability
Pattabiraman, D. R., Bierie, B., Kober, K. I., Thiru, P., Krall, J. A., Zill, C., Reinhardt, F., Tam, W. L., & Weinberg, R. A. (2016) · Science · doi:10.1126/science.aad3680 · Cited by 332 · cited 2×
“Targeting cellular surface markers, including CD133 [160], CD90 [161], CD33 [162], and PKA [163]; key pathways, such as the Notch, Hedgehog, Wnt, and NF-kB signaling pathways [164]; and transporters, including ABC transporters [165], have been detected in CSCs. Studies have sought ways to specifically target these cel…”
BackgroundTranslational value of mouse models in oncology drug development
Gould, S. E., Junttila, M. R., & de Sauvage, F. J. (2015) · Nature Medicine · doi:10.1038/nm.3853 · Cited by 293
Cell line misidentification: the beginning of the end
American Type Culture Collection Standards Development Organization Workgroup ASN-0002 (2010) · Nature Reviews Cancer · doi:10.1038/nrc2852 · Cited by 266
Tuntland, T., Ethell, B., Kosaka, T., Blasco, F., Zang, R. X., Jain, M., Gould, T., & Hoffmaster, K. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00174 · Cited by 239
Bodoky, G., Timcheva, C., Spigel, D. R., La Stella, P. J., Ciuleanu, T. E., Pover, G., & Tebbutt, N. C. (2012) · Investigational New Drugs · doi:10.1007/s10637-011-9687-4 · Cited by 236 · cited 1×
“One promising example of the application of the GEM model for anticancer development is selumetinib (clinical Phase I/II/III), which is designed for the treatment of multiple cancer types, including triple-negative breast cancer [84], nonsquamous cell lung cancer [85], pancreatic cancer [86], and neurofibroma [87,88].”
BackgroundElgogary, A., Xu, Q., Poore, B., Alt, J., Zimmermann, S. C., Zhao, L., Fu, J., Chen, B., Xia, S., Liu, Y., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1611406113 · Cited by 234
Three-Dimensional In Vitro Co-Culture Model of Breast Tumor using Magnetic Levitation
Jaganathan, H., Gage, J., Leonard, F., Srinivasan, S., Souza, G. R., Dave, B., & Godin, B. (2014) · Scientific Reports · doi:10.1038/srep06468 · Cited by 231
An Ancient, Unified Mechanism for Metformin Growth Inhibition in C. Elegans and Cancer
Wu, L., Zhou, B., Oshiro-Rapley, N., Li, M., Paulo, J. A., Webster, C. M., Mou, F., Kacergis, M. C., Talkowski, M. E., Carr, C. E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.055 · Cited by 227 · cited 2×
“The cancer prevention and anticancer activities of metformin have been demonstrated in cell-based assays [180,181], animal models [181,182], and controlled population studies [183].”
BackgroundTNIK inhibition abrogates colorectal cancer stemness
Masuda, M., Uno, Y., Ohbayashi, N., Ohata, H., Mimata, A., Kukimoto-Niino, M., Moriyama, H., Kashimoto, S., Inoue, T., Goto, N., et al. (2016) · Nature Communications · doi:10.1038/ncomms12586 · Cited by 168
Adult cancer clinical trials that fail to complete: an epidemic?
Stensland, K. D., McBride, R. B., Latif, A., Wisnivesky, J., Hendricks, R., Roper, N., Boffetta, P., Hall, S. J., Oh, W. K., & Galsky, M. D. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju229 · Cited by 161
Genetically Engineered Mouse Models: Closing the Gap between Preclinical Data and Trial Outcomes
Singh, M., Murriel, C. L., & Johnson, L. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2786 · Cited by 125 · cited 8×
“GEM models aim to manipulate the mouse genome to introduce the germline mutation or conditional mutations for different tumor types.”
BackgroundInfluentialHanke, T. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69651-7 · Cited by 65
Cited by
Targeting the IDO1/TDO2–KYN–AhR Pathway for Cancer Immunotherapy – Challenges and Opportunities
Cheong, J. E., & Sun, L. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.11.007 · Cited by 487
Metallodrugs in cancer nanomedicine
Peña, Q., Wang, A., Zaremba, O., Shi, Y., Scheeren, H. W., Metselaar, J. M., Kiessling, F., Pallares, R. M., Wuttke, S., & Lammers, T. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00468a · Cited by 259
3D-3-culture: a tool to unveil macrophage plasticity in the tumour microenvironment
Rebelo, S. P., Pinto, C., Martins, T. R., Harrer, N., Estrada, M. F., Loza-Alvarez, P., Cabeçadas, J., Alves, P. M., Gualda, E. J., Sommergruber, W., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.02.030 · Cited by 227
Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA
Wu, L., Ingle, T., Liu, Z., Zhao-Wong, A., Harris, S., Thakkar, S., Zhou, G., Yang, J., Xu, J., Mehta, D., et al. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-2628-5 · Cited by 80
Self-citationApplication of LDH assay for therapeutic efficacy evaluation of ex vivo tumor models
Cox, M. C., Mendes, R., Silva, F., Mendes, T. F., Zelaya-Lazo, A., Halwachs, K., Purkal, J. J., Isidro, I. A., Félix, A., Boghaert, E. R., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-97894-0 · Cited by 58
“Culture media from a well without cells was collected to determine the LDH levels in the sera, which was discounted (2) GR(ro) = 2 log2 (”
Method
Metadata
- Authors
- Liu, Z., Delavan, B., Roberts, R., & Tong, W.
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2017-10
- Volume
- 38
- Issue
- 10
- Pages
- 852-872
- ISSN
- 0165-6147 (ISSN-L)
- OpenAlex
- W2734862811
- Cited by
- 94
- References
- 53
- FWCI
- 0.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.